https://www.selleckchem.com/pr....oducts/enfortumab-ve
6% (338/1181) in 2007-2012 to 33.0% (310/938) in 2013-2017 (p=0.03). Age and performance status were independent predictors for SACT treatment; advanced age and higher performance status were associated with lower SACT treatment rates. Although developments in SACT during 2007-2017 correspond to some changes in survival for treated patients with advanced NSCLC, treatment rates remain low and the prognosis for all patients remains poor. Although developments in SACT during 2007-2017 correspond to some changes in survival
Beğen
Yorum Yap
Paylaş
